C
SRPT icon

Covestor’s Sarepta Therapeutics SRPT Stock Holding History

Covestor’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6K Buy
329
+20
+6% +$378 ﹤0.01% 1851
2026
Q1 		$7K Sell
309
-544
-64% -$10.5K ﹤0.01% 1691
2025
Q4 		$18K Sell
853
-1,936
-69% -$40.8K 0.01% 1334
2025
Q3 		$53K Buy
2,789
+2,553
+1,082% +$45.5K 0.03% 882
2025
Q2 		$4K Buy
236
+91
+63% +$3.88K ﹤0.01% 1774
2025
Q1 		$9K Hold
145
– – 0.01% 1586
2024
Q4 		$18K Sell
145
-17
-10% -$2.08K 0.01% 1256
2024
Q3 		$20K Hold
162
– – 0.01% 1216
2024
Q2 		$26K Sell
162
-2
-1% -$257 0.02% 1108
2024
Q1 		$21K Buy
164
+78
+91% +$9.55K 0.01% 1206
2023
Q4 		$8K Hold
86
– – 0.01% 1695
2023
Q3 		$10K Sell
86
-2
-2% -$226 0.01% 1443
2023
Q2 		$10K Sell
88
-501
-85% -$64.6K 0.01% 1457
2023
Q1 		$81K Sell
589
-152
-21% -$19.7K 0.07% 499
2022
Q4 		$96K Sell
741
-266
-26% -$30.8K 0.08% 406
2022
Q3 		$111K Buy
1,007
+831
+472% +$83.8K 0.1% 305
2022
Q2 		$13K Sell
176
-1
-0.6% -$74 0.01% 1126
2022
Q1 		$14K Buy
177
+77
+77% +$5.9K 0.01% 1194
2021
Q4 		$9K Buy
+100
New +$8.55K 0.01% 1062

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Covestor's SRPT Position: Q2 2026 in Review

Covestor increased its Sarepta Therapeutics (SRPT) stake by 6.5% in Q2 2026, buying an estimated $378 and bringing the position to 329 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1851.

Covestor first reported a position in SRPT in Q4 2021 and has held it in 19 quarters since. The position peaked at $111K in Q3 2022. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Covestor held 329 shares of Sarepta Therapeutics worth $6K as of Q2 2026.
  • Covestor bought 20 Sarepta Therapeutics shares in Q2 2026, an estimated $378.
  • Sarepta Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #1851 holding.
  • Covestor first reported a position in Sarepta Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Covestor's Sarepta Therapeutics position peaked at $111K in Q3 2022.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.